# A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors

> **NCT05949632** · PHASE1,PHASE2 · TERMINATED · sponsor: **Incyte Corporation** · enrollment: 5 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** INCB099280
- **DRUG:** axitinib

## Key facts

- **NCT ID:** NCT05949632
- **Lead sponsor:** Incyte Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-04-16
- **Primary completion:** 2025-06-06
- **Final completion:** 2025-06-06
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** This was a strategic business decision. There were no safety concerns contributing to this decision.
- **Last updated:** 2025-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05949632

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05949632, "A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT05949632. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*